07 August 2015: Articles
A Case of Late Implantable Cardiac Device Infection with Aspergillus in an Immunocompetent Host
Unusual clinical course, Challenging differential diagnosis, Educational Purpose (only if useful for a systematic review or synthesis)
Archana Kodali ABCDEF , Koroush Khalighi ACDEFDOI: 10.12659/AJCR.893413
Am J Case Rep 2015; 16:520-523
Abstract
BACKGROUND: With the increasing use of cardiac implantable electronic devices (CIED), there has been an associated increase in rate of complications. Infection accounts for about 1% of these, of which only a handful were reported secondary to Aspergillus fumigatus. All of these were seen in chronically-ill patients with several co-morbid conditions within a few years of implantation. None have been reported in an otherwise immunocompetent patient at 7 years after CIED implantation.
CASE REPORT: A 67-year-old woman with symptomatic sick sinus syndrome required a pacemaker 15 years ago with subsequent revision 7 years prior due to battery depletion. She now presented with a left pectoral non-tender mass that developed over several weeks. She denied history of recent fever, trauma, or infection. An elective pacemaker revision and pocket exploration led to the drainage of 150 cc of serosanguineous discharge from the pocket. She received peri-procedural prophylaxis with Vancomycin, but later, wound cultures grew Aspergillus fumigatus. She underwent complete removal of the pacemaker system along with a 6-week course of voriconazole and is doing well.
CONCLUSIONS: Even though Staphylococcus aureus causes most CIED infections, there should be a suspicion for fungal organisms, especially in culture-negative infections, in immunocompromised states like diabetes mellitus or with minimal improvement on antibiotics. If not treated appropriately, aspergillosis may have catastrophic outcomes, including endocarditis, often leading to death. Appropriate treatment should include immediate initiation of antifungals and removal of the CIED. It is still unclear why an immunocompetent patient developed aspergillosis, but appropriate management helped avoid a grave outcome.
Keywords: Aspergillus, Aspergillosis - therapy, Pacemaker, Artificial - adverse effects, Prosthesis-Related Infections - therapy, Sick Sinus Syndrome - therapy
Background
Infections account for about 1% of the complications associated with the use of cardiovascular implantable electronic devices (CIED), in spite of aggressive precautions [1]. The most common organism implicated is
Case Report
A 67-year-old woman had a history of hypertension, atrial tachycardia, and symptomatic sick sinus syndrome requiring a pacemaker insertion almost 16 years ago had subsequent uneventful revision 7 years ago due to battery repletion. She had presented in the out-patient setting about 6 months prior for swelling on the left side of the chest.
On examination, it was presumed to be a hematoma near the pacemaker pocket site. She had denied any trauma or injury. She had no fever, recent infection or any other signs suggestive of infection elsewhere. The site was non-tender and had no features suggestive of cellulitis. Conservative management with warm-compresses was started which helped decrease the swelling, only to have it recur again. Given the location of the presumed hematoma and the recurrence, there was a concern for fluid collection in the pacemaker pocket. As her pacemaker had reached ERI (elective replacement interval) due to battery depletion, she was scheduled for a pacemaker revision.
On admission, she had no complaints apart from the swelling. She was afebrile and her white blood cell count was also normal at 8300 cells/mcL. After the incision was done, there was drainage of about 150 cc of serosanguineous fluid from the pocket which was sent for laboratory analysis, including gram stain, culture and sensitivity and cytology. She underwent standard peri-operative antibiotics therapy with Vancomycin due to a history of penicillin sensitivity. Later, the pocket site fluid culture grew
She has no history of diabetes mellitus, kidney disease, malignancies or HIV exposure. Infectious disease work-up including panculture (blood culture, urine culture and sputum cultures), HIV titers, hepatitis viral panel, chest X-ray and CT scan of the chest and abdomen were performed and they were within normal limits. In addition, she had an out-patient mammogram which showed no evidence for breast cancer. Social history and exposure history (inclusive of mold) was also reviewed to rule out any potential cause or source of the fungal infection.
She underwent extraction of the entire pacemaker system with debridement of the pocket, and completed six weeks course of anti-fungal therapy with Voriconazole and has been doing well. She underwent a right pectoral pacemaker implantation once she was cleared from her acute infection.
Discussion
POCKET INFECTIONS:
Deeper infections – which include device-related endocarditis. Alternatively, device infections may be classified by the mode of infection: Primary infections – when the source of infection is from the device due to contamination at the time of implant Secondary infection – where the leads get infected due to bacteremia from a different source and can also progress to pocket or generator infection. Source of infection can be exogenous (from infected devices) or endogenous.
In support of endogenous acquisition, an association has been noted between the presence of preaxillary skin flora and the pathogens isolated from pacemaker infection. Therefore, aggressive peri-operative wound care has shown to reduce the incidence of infections in patients undergoing CIED implants.
ETIOLOGY:
Early infections are most commonly caused by Staphylococcus aureus [2] of which methicillin-resistant Staphylococcus aureus (MRSA) would account for about half. Late infections are most commonly by Streptococcus5. Corynebacterium species, Propionibacterium acnes, Gram-negative bacilli including Pseudomonas aeruginosa, and Candida species account for a minority of CIED infections [2,4]. Fungi other than Candida and non-tuberculosis mycobacteria are rarely identified as pathogens in CIED infection with the incidence being less than 2% [3].
ASPERGILLUS: Aspergillus fumigatus is a significant and potentially life-threatening fungus, seen especially in an immunocompromised host. It is particularly abundant in the air of buildings with deficient ventilation systems and near construction sites. It most commonly affects the respiratory tract, but other sites, including skin, have also been identified as portals of entry [4] and many times, the source of infection remains unknown [10].
Only a handful of cases have been reported with Aspergillus as the cause for CIED infections. One of the first cases reported was back in the 1980s and almost all of them in that era resulted in death with diagnosis being made post-mortem [5,11]. Commonly seen risk factors include immunosuppression, long term antibiotic or corticosteroid use, diabetes mellitus, heart failure or chronic kidney disease, prolonged hospitalization or cardiothoracic surgery [12].
The majority of these cases have been seen with lead infections and endocarditis often with tricuspid valve vegetations [4]. An article published in 2007 [6] reviewed 15 cases of Aspergillus associated pacemaker and ICD infections, of which only two had pocket infections. So far only four cases have been reported in association with pacemaker pocket infection and all of these occurred either acutely or sub-acutely.
Pincus et al. [4] described a 54-year-old man who developed an infection at the pacemaker site just within a few days of having multiple procedures/revisions of the pacemaker. Even though he had no systemic signs of infection, the pacemaker site looked visibly infected with cultures of the pocket and lead eventually growing Aspergillus fumigatus. He was effectively treated with voriconazole and linezolid. In contrast, Izquierdo et al. [7] described two patients who developed pocket infections secondary to A. fumigatus but almost 1.5 to 2 years after device manipulation. Like Pincus et al., their cases also had risk factors like diabetes, but eventually did well with surgical and medical treatment. Cobo et al. [6] reported a 74-year-old woman presenting with pocket infection, which was later found to be from Aspergillus favus. An Echocardiogram in addition showed vegetations in the cardiac leads. She also did well after removal of the pacemaker system and with anti-fungal therapy.
The four cases described above had multiple manipulations of the pacemaker device and also had chronic disease like diabetes, which rendered the patient vulnerable to fungal infection. In addition, the time since implant to presentation varied from a few weeks to two years. In contrast, our patient had no chronic disease, nor any malignancy. Extensive investigations were done to rule out any occult malignancy and even HIV was tested. There was no history suggestive of exposure to mold either. She was healthy and was immunocompetent, yet she developed
If not diagnosed early and treated appropriately, fungal infections are associated with a high mortality because of lead involvement and thrombus formation. Pocket infections can be identified by cultures. But most often, they have a prolonged incubation period ranging anywhere from one day to two weeks. Diagnosing fungal endocarditis remains elusive because of negative blood cultures [13,14]. It has been reported that they are positive only in about 11% of cases [15], thus accounting for the high mortality. Once there is suspicion of Aspergillus infection, or when confirmed, immediate anti-fungal therapy should be initiated. As mentioned above, as it most often involves the leads and endocarditis, an echocardiogram is almost always recommended to evaluate the presence of lead and/or valve vegetations. Transthoracic echocardiograms may not be solely enough to identify the vegetations or thrombus so a transesophageal echocardiogram is suggested [13].
Treatment includes appropriate anti-fungal therapy, even before confirming the diagnosis with culture results. Anti-fungal agents like Amphotericin B, flucytosine and itraconazole have been used, but Voriconazole remains the first-choice [10]. Additionally, removal of the CIED system is strongly recommended, because of the possibility of large intravascular vegetations, for which plain medical therapy may be insufficient [13]. The procedure must be performed with caution in patients who are dependent on the pacemaker or ICD as mortality can be high, but patients tend to do well.
Conclusions
Even though the most commonly seen pathogens for CIED infections are
We should be aware that
References:
1.. Chu JD, Wilkoff BL, Lee I, Diagnosis and management of infections involving implantable electrophysiologic cardiac devices: Ann Intern Med, 2000; 133; 604-8, pmid: 11033588
2.. Dunn CJ, Ruder M, Deresinski SC: Pacing Clin Electrophysiol, 1996; 19; 2156-57, pmid: 8994959
3.. Baddour LM, Epstein AE, Erickson CC, Update on cardiovascular implantable electronic device infections and their management. a scientific statement from the American Heart Association. Endorsed by the Heart Rhythm Society: Circulation, 2010; 121; 458-77, pmid: 20048212
4.. Pincus J, Jahng M, Massie L, Lee SA: Med Mycol Case Rep, 2012; 1(1); 32-34, pmid: 24371732
5.. Moorman JR, Steenbergen C, Durack DT: Pacing Clin Electrophysiol, 1984; 7; 361-64, pmid: 6204287
6.. Cobo M, Ramos A, Toquero J: Eur J Clin Microbiol Infect Dis, 2007; 26(5); 357-61, pmid: 17443356
7.. Izquierdo R, Llorente C, Mayo J: Clin Cardiol, 2005; 28(1); 36-38, pmid: 15704531
8.. Khalighi K, Aung TT, Elmi F, The Role of prophylaxis topical antibiotics in cardiac device implantation: Pacing Clin Electrophysiol, 2014; 37(3); 304-11, pmid: 24164587
9.. Baddour LM, Cha Y, Wilson WR, Infections of cardiovascular implantable electronic devices: N Engl J Med, 2012; 367; 842-49, pmid: 22931318
10.. Marchena Yglesias PJ, Nieto Rodriguez JA, Arranz Garcia G: Eur J Intern Med, 2006; 17; 209-10, pmid: 16618457
11.. Gannon BR, Leong R, Childs TJ: Pathology, Research and Practice, 2004; 200; 641
12.. Leong R, Gannon BR, Childs TJ: Can J Cardiol, 2006; 22(4); 337-40, pmid: 16568159
13.. Cook RJ, Orszulak TA, Nkomo VT: Mayo Clin Proc, 2004; 79; 549-52, pmid: 15065620
14.. Kramer L, Corona RR, Sheff D, Eisenberg ES, Disseminated aspergillosis and pacemaker endocarditis: Pacing Clin Electrophysiol, 1985; 8; 225-29, pmid: 2580283
15.. Pillai J, Mubeen M, Chaudhari A, Dalmia B: Asian Cardiovasc Thorac Ann, 2012; 21(2); 211-14, pmid: 24532625
In Press
Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.949976
Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.950290
Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.950607
Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.950985
Most Viewed Current Articles
07 Dec 2021 : Case report
17,691,734
DOI :10.12659/AJCR.934347
Am J Case Rep 2021; 22:e934347
06 Dec 2021 : Case report
164,491
DOI :10.12659/AJCR.934406
Am J Case Rep 2021; 22:e934406
21 Jun 2024 : Case report
113,090
DOI :10.12659/AJCR.944371
Am J Case Rep 2024; 25:e944371
07 Mar 2024 : Case report
59,175
DOI :10.12659/AJCR.943133
Am J Case Rep 2024; 25:e943133






